In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Timo RückertCharité - Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Institute of Medical Immunology, Berlin, Germany.ORCID 0000-0003-1433-1372 Matthias GüntherDivision of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.ORCID 0000-0001-8077-8194 Oliver KnightCharité - Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Institute of Medical Immunology, Berlin, Germany.ORCID 0000-0002-0424-2379 Maximilian MandryCharité - Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Institute of Medical Immunology, Berlin, Germany.ORCID 0009-0004-9256-5443 Karl JunkerCharité - Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Institute of Medical Immunology, Berlin, Germany.
Thomas HöferDivision of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.ORCID 0000-0003-3560-8780 Chiara RomagnaniCharité - Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Institute of Medical Immunology, Berlin, Germany.ORCID 0000-0002-5167-7463 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MThe natural killer cell response against mouse cytomegalovirus infectionR01AI100874 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI Joseph Chai-Yuen Sun · 2012 to 2026
$7.4MTranscriptional control of NK cell metabolismR01AI155558 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI Joseph Chai-Yuen Sun · 2021 to 2026
$4.7MChromatin architecture regulating trained immunity in antiviral NK cellsR01AI189793 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI SUN, JOSEPH CHAI-YUEN · 2025 to 2025
$3.5MRegulation of Nfil3 in innate lymphocyte-mediated host immunityR01AI130043 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI SUN, JOSEPH CHAI-YUEN · 2017 to 2021
$2.8MInflammatory B Cells Defined by TIM-4 in the Alloimmune ResponseR56AI130034 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROTHSTEIN, DAVID M · 2017 to 2017
$371kInvestigating the molecular basis of context-dependent STAT3 function in NK cellsK99AI180360 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI GRASSMANN, SIMON · 2024 to 2025
$229kNCI NIH HHS P30 CA008748NIAID NIH HHS K99 AI180360NIAID NIH HHS R01 AI100874NIAID NIH HHS R01 AI130043NIAID NIH HHS R01 AI155558NIAID NIH HHS R01 AI189793NIAID NIH HHS R56 AI130034
6 · The paper itselfAbstract
Adaptive immune memory relies on selective clonal expansion and persistence of lymphocyte populations. Whether and how clonal selection occurs in innate lymphocytes that lack rearranged antigen receptors remains poorly understood. Here, we used somatic genetics to reconstruct the natural history of human natural killer (NK) cell responses to cytomegalovirus infection. Across a large cohort of healthy seropositive individuals, we found strong clonal dominance in memory NK cells consistent with clonal selection. Dominant memory NK cell clones were marked by coherent receptor and chromatin configurations, emerged early in life and diversified into genetically related subclones. Both an excess of coding mutations, and the reconstructed population dynamics of the dominant clones, provided evidence for positive selection acting on somatic genetic variation. We identified somatic loss-of-function mutations in the chromatin modifier
Identifiers
PMID42780023
PMCPMC13596417
What OpenQuestion holds
Textmetadata
Read underepoch 390